The early detection of Alzheimer’s disease is set to become faster and more cost-effective after researchers developed a first-of-its-kind finger-prick blood test to detect the disease before symptoms progress.
Engineers at Monash University developed a small, handheld device that uses world-first patented sensor technology to detect ultra-low concentrations of disease markers in blood within minutes. This innovation is expected to enable GPs to diagnose Alzheimer’s at an early stage.
Associate Professor Sudha Mokkapati from Monash Materials Science and Engineering, developed the proof-of-concept electronic sensor, stating that the device is “simple to use, low-cost and portable so it could be made widely accessible to GPs to screen patients right at the point-of-care”.
“Detecting very early disease in large populations could dramatically change the trajectory of this burdening disease for many patients, and shave millions off associated healthcare costs,” Mokkapati said.
“We’ve completed testing that shows the technology is highly advanced by design and capable of detecting ultra low levels of several disease biomarkers in blood.”
Given that the number of Australians diagnosed with dementia is set to double by 2054, the quick blood test could provide earlier, more efficient diagnosis, offering timely intervention and management of Alzheimer’s, according to Associate Professor Matthew Pase from Monash’s School of Psychological Sciences.
“Most patients with neurodegenerative disease are typically diagnosed at advanced stages. Sadly, treatments targeting late-onset disease provide limited therapeutic benefit,” Pase said.
“Earlier screening could change the outlook for many patients diagnosed with cognitive impairment through a greater chance of halting or slowing symptom development and the rapid progression of the disease.”
Researchers are now focusing on conducting clinical validation and securing the necessary funding to ensure that the innovation becomes widely accessible.
-with AAP.